PRKAR1A and neoplasm: In addition, three germline PRKAR1A variants in the cAMP binding domain A (c.547G>T (p.A183Y), c.638C>A (p.213D), and c.438A>T (p.R146S)) had been reported and the functional studies in vitro have demonstrated that these missense variants might enhance the PKA activity leading to accelerating the tumor genesis.